CSPC pharmaceutical announces leadership changes, appoints new CEO and COO

Effective December 19, 2025, Zhang Cuilong will step down as vice-chairman, chief executive officer (CEO), and authorised representative due to work reassignment, but will remain an executive director. Cai Lei has been appointed as vice-chairman, executive director, CEO, and authorised representative. Cai, 45, joined the Group in April 2014 and currently serves as an executive president and vice president of the U.S. R&D division. His monthly salary is $17,000, and he holds 40,000 shares of the company.

In a related move, Wei Qingjie, 56, who joined the Group in May 2019, has been appointed as vice-chairman, executive director, and chief operating officer. Wei is currently the Group's executive president and chief coordinator and has personal interests in 300,000 shares of the company, along with unvested share awards of 1,400,000 shares. His monthly salary is RMB60,000.

The board expressed gratitude to Zhang for his contributions. These changes are part of a broader leadership adjustment within the Group, aimed at strengthening its operational and strategic direction.